|
CRTC3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.15463194561016E-14 |
| Normal-vs-Stage2 |
6.44410003136642E-09 |
| Normal-vs-Stage3 |
1.66533453693773E-15 |
| Normal-vs-Stage4 |
4.25269819359642E-11 |
| Stage1-vs-Stage2 |
6.106400E-01 |
| Stage1-vs-Stage3 |
6.421800E-02 |
| Stage1-vs-Stage4 |
2.533800E-01 |
| Stage2-vs-Stage3 |
4.336400E-01 |
| Stage2-vs-Stage4 |
6.316200E-01 |
| Stage3-vs-Stage4 |
8.025200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
2.843400E-04 |
| Normal-vs-Asian |
7.46590012035142E-10 |
| Caucasian-vs-AfricanAmerican |
1.564650E-01 |
| Caucasian-vs-Asian |
7.998200E-01 |
| AfricanAmerican-vs-Asian |
3.269800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.84816614737338E-12 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
2.840000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.88316029436919E-12 |
| Normal-vs-Age(41-60Yrs) |
2.31814567541733E-13 |
| Normal-vs-Age(61-80Yrs) |
1.30340183090993E-13 |
| Normal-vs-Age(81-100Yrs) |
3.70440000000416E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.235000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.794200E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.691360E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.701700E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.947800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.623400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.143700E-03 |
| Classical-VS-Follicular |
5.704600E-03 |
| Classical-VS-Other |
6.050200E-01 |
| Classical-VS-Normal |
9.30939991761193E-10 |
| Tall-VS-Follicular |
5.519600E-01 |
| Tall-VS-Other |
5.341600E-01 |
| Tall-VS-Normal |
1.46715972704214E-12 |
| Follicular-VS-Other |
6.547200E-01 |
| Follicular-VS-Normal |
2.18502993476477E-12 |
| Other-VS-Normal |
3.581500E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.55111512312578E-16 |
| Normal-vs-N1 |
8.43725089794134E-12 |
| N0-vs-N1 |
4.086600E-01 |
|
|
